Dabigatran (Pradaxa)


Indications

Systemic Embolism Prevention in Nonvalvular Atrial Fibrillation (see Atrial Fibrillation, [[Atrial Fibrillation]])

Venous Thromboembolism-Deep Venous Thrombosis (DVT)/Acute Pulmonary Embolism (PE) (see Deep Venous Thrombosis, [[Deep Venous Thrombosis]] and Acute Pulmonary Embolism, [[Acute Pulmonary Embolism]])

Venous Thromboembolism Prophylaxis Post-Knee and Hip Replacement (see Deep Venous Thrombosis, [[Deep Venous Thrombosis]])


Pharmacology

Pharmacokinetics

Metabolism

Drug Interactions


Administration

PO Dosing

Hepatic Dose-Adjustment

Renal Dose-Adjustment

Venous Thromboembolism

Non-Valvular Atrial Fibrillation

Venous Thromboembolism Prophylaxis

Effect on Anticoagulation Tests

Conversion from/to Other Anticoagulants

Conversion from Dabigatran

Conversion to Dabigatran

Abrupt Discontinuation of Dabigatran

Management of Dabigatran Anticoagulation for Procedures

Reversal of Anticoagulation


Adverse Effects

Hemorrhagic Adverse Effects

General Comments

Post-Hip Replacement or Knee Replacement DVT Prophylaxis Trials

Atrial Fibrillation Trials

Venous Thrombembolism Trials

Comparative Rates of Hemorrhage Between Coumadin and Novel Oral Anticoagulants

Types of Hemorrhage

Other Adverse Effects


References